KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Notes Payables (2016 - 2021)

Abbott Laboratories' Notes Payables history spans 13 years, with the latest figure at $197.0 million for Q3 2021.

  • For Q3 2021, Notes Payables fell 5.29% year-over-year to $197.0 million; the TTM value through Sep 2021 reached $197.0 million, down 5.29%, while the annual FY2020 figure was $213.0 million, 5.97% up from the prior year.
  • Notes Payables for Q3 2021 was $197.0 million at Abbott Laboratories, down from $199.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $341.0 million in Q2 2018 and bottomed at $197.0 million in Q3 2021.
  • The 5-year median for Notes Payables is $205.0 million (2020), against an average of $213.6 million.
  • The largest annual shift saw Notes Payables crashed 92.46% in 2017 before it skyrocketed 56.42% in 2018.
  • A 5-year view of Notes Payables shows it stood at $206.0 million in 2017, then dropped by 2.91% to $200.0 million in 2018, then rose by 0.5% to $201.0 million in 2019, then grew by 5.97% to $213.0 million in 2020, then fell by 7.51% to $197.0 million in 2021.
  • Per Business Quant, the three most recent readings for ABT's Notes Payables are $197.0 million (Q3 2021), $199.0 million (Q2 2021), and $199.0 million (Q1 2021).